Treatment of congenital nephrogenic diabetes insipidus by hydrochlorothiazide and cyclooxygenase-2 inhibitor.

Author: AlonUri S, PattaragarnAnirut

Paper Details 
Original Abstract of the Article :
A 1-month-old male infant presented with failure to thrive, polyuria, and severe hypernatremic dehydration. Based on family history, lack of response to vasopressin, and normal sonography of the urinary system, the diagnosis of congenital nephrogenic diabetes insipidus (cNDI) was established. The in...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1007/s00467-003-1195-0

データ提供:米国国立医学図書館(NLM)

A New Approach to Treating Congenital Nephrogenic Diabetes Insipidus

This research explores a novel therapeutic approach to treat congenital nephrogenic diabetes insipidus (cNDI), a rare genetic disorder affecting the kidneys' ability to concentrate urine. The study investigated the use of hydrochlorothiazide (HCTZ), a diuretic, combined with a cyclooxygenase-2 (COX-2) inhibitor, rofecoxib, to manage the symptoms of cNDI. The authors report a positive outcome in a young infant diagnosed with cNDI, demonstrating a significant reduction in urinary free water losses and improved growth and development. The study suggests that this combination therapy could be a viable option for treating infantile cNDI.

A Promising Therapy for a Rare Condition

This study demonstrates the potential of a novel combination therapy for treating congenital nephrogenic diabetes insipidus (cNDI). The combination of hydrochlorothiazide (HCTZ) and rofecoxib effectively reduced urinary free water losses, leading to improved growth and development in the infant patient. This finding could offer hope for families dealing with this challenging condition.

Managing Congenital Nephrogenic Diabetes Insipidus

This research highlights the importance of exploring new treatment strategies for rare conditions like cNDI. The successful use of HCTZ and rofecoxib in this case study suggests a promising avenue for managing the symptoms of cNDI. The findings encourage further research into the long-term efficacy and safety of this combination therapy.

Dr.Camel's Conclusion

Just like the desert has its own secrets, the human body holds many mysteries. This research uncovers a new way to manage cNDI, a rare condition that affects the kidneys' ability to regulate water balance. The combination of HCTZ and rofecoxib offers a promising therapeutic option for families facing this challenging condition. As we continue to explore these mysteries, we may find even more effective treatments for rare diseases, making a real difference in people's lives. Just like the desert reveals its beauty under the sun, so too can medical breakthroughs shine light on the world of human health.

Date :
  1. Date Completed 2004-06-09
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

12883974

DOI: Digital Object Identifier

10.1007/s00467-003-1195-0

Related Literature

Article Analysis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.